Troy Edward Wilson Corrects Trust Ownership Of His $1.5 Million Kura Oncology Purchase
The CEO's trade terms and total holdings stayed unchanged; he had bought shares at a higher price in August.
Troy Edward Wilson, president and CEO of Kura Oncology, which develops and sells targeted cancer medicines, corrected the ownership classification of his $1.5 million share purchase in an amended SEC report Tuesday. The 200,000 shares bought Friday and Monday belonged to a trust; the correction left the prices, quantities and total holdings unchanged.
The Shares Belong To A Trust
Wilson bought the shares through One Fish Two Fish Revocable Trust. Tuesday's amendment corrected an insider-trading report filed Monday that had classified those purchases as shares he held directly.
Average purchase prices for Wilson's two batches were $7.42 for the 101,119 shares bought Monday and $7.63 each for the 98,881 shares bought Friday. Across the purchases, he paid an average $7.52 per share.
Wilson reported 1,414,650 shares after the purchases, including 435,456 held directly and 979,194 held through trusts. One Fish Two Fish accounted for 679,194 of those trust-held shares. The purchases represented about 14% of his reported holdings.
Buying Below His August Price
Wilson's reported stake was worth an estimated $10.6 million at Tuesday's closing price of $7.49. KURA shares were down about 32% this year and about 37% over the past 12 months as of Monday's close.
His earlier buying came at a higher price. Previous SEC reports showed that Wilson bought 100,000 shares on August 24 for about $12.39 each, spending $1.2 million.
KOMZIFTI Anchors Kura's Business
Kura's commercial medicine, KOMZIFTI, is an oral treatment sold in the United States for adults whose acute myeloid leukemia has returned or resisted treatment. Eligible patients have a susceptible nucleophosmin 1 mutation and no satisfactory alternative treatment options.
Kura records all U.S. sales of KOMZIFTI, also called ziftomenib. It splits commercialization profits and losses equally with Kyowa Kirin, which handles commercialization outside the United States.
Its research includes ziftomenib combinations for leukemia and gastrointestinal tumors. Kura is also studying darlifarnib combinations for solid tumors, including kidney, lung, colorectal and pancreatic cancers.
The amendment changed how Wilson's purchase was classified, while preserving the size of his investment and his reported ownership.
Sources
- Form 4/A — Troy Edward Wilson (KURA) — SEC EDGAR